CAS NO: | 19660-77-6 |
包装 | 价格(元) |
50mg | 电议 |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
Storage | Store at -20°C |
M.Wt | 596.67 |
Cas No. | 19660-77-6 |
Formula | C34H36N4O6 |
Synonyms | Ce6 |
Solubility | ≤30 mg/mL in DMSO |
Chemical Name | (7S,8S)-3-carboxy-5-(carboxymethyl)-13-ethenyl-18-ethyl-7,8-dihydro-2,8,12,17-tetramethyl-21H,23H-porphine-7-propanoic acid |
Canonical SMILES | CC1=C2NC(/C(CC(O)=O)=C(N=C3/C=C4N/C(C(C=C)=C\4C)=C\C5=N/C(C(CC)=C5C)=C\2)/[C@@H](CCC(O)=O)[C@@H]3C)=C1C(O)=O |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
Chlorin e6 (Ce6) is a second-generation photosensitizer with antitumor activity when used in conjunction with irradiation.
In a mouse model of implanted fibrosarcoma, Ce6 (2.5-10 mg/kg, i.v. with irradiation at 50-200 J/cm2) led to complete tumor loss following varying levels of irradiation[1].
A formulation including Ce6 was tested in a Phase I clinical study for patients with bronchogenic early superficial squamous cell carcinoma with positive results (40 mg/m2, i.v. with laser irradiation at 100 J/cm2)[2]. The same dosing paradigm in a Phase II clinical trial for early stage lung cancer patients led to a complete response in 82.9% of patients[3].
References:
[1]. Katsumi T A, Aizawa K, Kuroiwa Y, et al. Photodynamic therapy with a diode laser for implanted fibrosarcoma in mice employing mono-L-aspartyl chlorin E6. Photochem. Photobiol, 1996, 64(4): 671-675.
[2]. Furukawa K, Okunaka T, Tsuchida T. A phase I clinical study of photodynamic therapy for early stage lung carcinoma using ME2906 and a diode laser system. Porphyrins, 1998, 7: 199-206.
[3]. Kato H, Furukawa K, Sato M, et al. Phase II clinical study of photodynamic therapy using mono-L-aspartyl chlorin e6 and diode laser for early superficial squamous cell carcinoma of the lung. Lung Cancer, 2003, 42(1): 103-111.